OAM
KNSA icon

Oberweis Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Oberweis Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.4M Buy
413,034
+94,400
+30% +$4.9M 0.55% 69
2026
Q1 		$15.3M Buy
318,634
+5,834
+2% +$258K 0.45% 87
2025
Q4 		$12.9M Buy
312,800
+7,600
+2% +$305K 0.47% 85
2025
Q3 		$11.9M Hold
305,200
– – 0.45% 84
2025
Q2 		$8.44M Buy
305,200
+68,000
+29% +$1.73M 0.37% 98
2025
Q1 		$5.27M Hold
237,200
– – 0.26% 128
2024
Q4 		$4.69M Buy
237,200
+36,200
+18% +$826K 0.22% 144
2024
Q3 		$5.02M Buy
+201,000
New +$4.9M 0.26% 134

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Oberweis Asset Management's KNSA Position: Q2 2026 in Review

Oberweis Asset Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 30% in Q2 2026, buying an estimated $4.9M and bringing the position to 413,034 shares worth $26.4M. The position accounts for 0.55% of the portfolio, ranked #69.

Oberweis Asset Management first reported a position in KNSA in Q3 2024 and has held it in 8 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Oberweis Asset Management held 413,034 shares of Kiniksa Pharmaceuticals worth $26.4M as of Q2 2026.
  • Oberweis Asset Management bought 94,400 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $4.9M.
  • Kiniksa Pharmaceuticals made up 0.55% of Oberweis Asset Management's portfolio in Q2 2026, its #69 holding.
  • Oberweis Asset Management first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Oberweis Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.